JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
QUICK SEARCH:   [advanced]


     

J Am Coll Cardiol, 2005; 45:989-994, doi:10.1016/j.jacc.2004.11.060
© 2005 by the American College of Cardiology Foundation
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (32)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ge, L.
Right arrow Articles by Colombo, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ge, L.
Right arrow Articles by Colombo, A.

CLINICAL RESEARCH: INTERVENTIONAL CARDIOLOGY

Treatment of saphenous vein graft lesions with drug-eluting stents

Immediate and midterm outcome

Lei Ge, MD*,{dagger}, Ioannis Iakovou, MD*, Giuseppe M. Sangiorgi, MD*, Alaide Chieffo, MD*, Gloria Melzi, MD*, John Cosgrave, MD*, Matteo Montorfano, MD*, Iassen Michev, MD*, Flavio Airoldi, MD*, Mauro Carlino, MD*, Nicola Corvaja, MD* and Antonio Colombo, MD, FACC*,*

* EMO Centro Cuore Columbus and San Raffaele Hospital, Milan, Italy
{dagger} Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai, China

Manuscript received September 14, 2004; revised manuscript received October 29, 2004, accepted November 2, 2004.

* Reprint requests and correspondence: Dr. Antonio Colombo, EMO Centro Cuore Columbus, 48 Via M. Buonarroti, 20145 Milan, Italy (Email: info{at}emocolumbus.it).

OBJECTIVES: The purpose of the present report was to evaluate clinical and angiographic outcomes of drug-eluting stent (DES) implantation in saphenous vein graft (SVG) lesions.

BACKGROUND: The safety and efficacy of DES implantation for the treatment SVG lesions remains uncertain.

METHODS: We evaluated in-hospital and six-month outcomes in 61 consecutive patients treated with DES in SVG lesions from March 2002 to March 2004 (DES group), as compared to 89 consecutive patients treated with bare-metal stents (BMS) in the 24 months immediately before the introduction of DES (BMS group). Major adverse cardiac events (MACE) including death, myocardial infarction, target lesion revascularization (TLR), and target vessel revascularization (TVR) were recorded in-hospital and at six-month follow-up.

RESULTS: The rate of in-hospital MACE was similar between the two groups (6.6% vs. 5.6%, p = 1.0). Cumulative MACE at six months was 11.5% in the DES group and 28.1% in the BMS group (p = 0.02). The DES group had a significantly lower incidence of in-segment restenosis (10.0% vs. 26.7%, p = 0.03), TLR (3.3% vs. 19.8%, p = 0.003), and TVR (4.9% vs. 23.1%, p = 0.003). By Cox regression analysis, diabetes (hazard ratio [HR]: 3.03; 95% confidence interval [CI]: 1.33 to 6.90; p = 0.008), usage of BMS (HR: 2.53; 95% CI: 1.07 to 5.97; p = 0.03), and age of SVG (HR: 1.10; 95% CI: 1.02 to 1.19; p = 0.02) were identified as predictors of MACE at six-month follow-up.

CONCLUSIONS: Compared to BMS implantation, DES implantation in SVG lesions appears safe with favorable and improved mid-term outcomes.

Abbreviations and Acronyms
  BMS = bare-metal stent
  CI = confidence interval
  DES = drug-eluting stent
  HR = hazard ratio
  MACE = major adverse cardiac events
  MI = myocardial infarction
  MLD = minimal lumen diameter
  RVD = reference vessel diameter
  SVG = saphenous vein graft
  TLR = target lesion revascularization
  TVR = target vessel revascularization




This article has been cited by other articles:


Home page
 HeartHome page
N Melikian and W Wijns
Drug-eluting stents: a critique
Heart, February 1, 2008; 94(2): 145 - 152.
[Abstract] [Full Text] [PDF]

Home page
 Card Surg AdultHome page
J. M. Wilson and J. T. Willerson
Myocardial Revascularization with Percutaneous Devices
Card. Surg. Adult, January 1, 2008; 3(2008): 573 - 598.
[Full Text]

Home page
 Card Surg AdultHome page
G. V. Gonzalez-Stawinski and B. W. Lytle
Coronary Artery Reoperations
Card. Surg. Adult, January 1, 2008; 3(2008): 711 - 732.
[Full Text]

Home page
 CirculationHome page
A. Colombo and A. Chieffo
Drug-Eluting Stent Update 2007: Part III: Technique and Unapproved/Unsettled Indications (Left Main, Bifurcations, Chronic Total Occlusions, Small Vessels and Long Lesions, Saphenous Vein Grafts, Acute Myocardial Infarctions, and Multivessel Disease)
Circulation, September 18, 2007; 116(12): 1424 - 1432.
[Full Text] [PDF]

Home page
 JAMAHome page
N. Beohar, C. J. Davidson, K. E. Kip, L. Goodreau, H. A. Vlachos, S. N. Meyers, K. H. Benzuly, J. D. Flaherty, M. J. Ricciardi, C. L. Bennett, et al.
Outcomes and Complications Associated With Off-Label and Untested Use of Drug-Eluting Stents
JAMA, May 9, 2007; 297(18): 1992 - 2000.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
H. K. Win, A. E. Caldera, K. Maresh, J. Lopez, C. S. Rihal, M. A. Parikh, J. F. Granada, S. Marulkar, D. Nassif, D. J. Cohen, et al.
Clinical Outcomes and Stent Thrombosis Following Off-Label Use of Drug-Eluting Stents
JAMA, May 9, 2007; 297(18): 2001 - 2009.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
H.-P. B.-L. Rocca, C. Kaiser, M. Pfisterer, and on behalf of the BASKET Investigators
Targeted stent use in clinical practice based on evidence from the BAsel Stent Cost Effectiveness Trial (BASKET)
Eur. Heart J., March 2, 2007; 28(6): 719 - 725.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
R. Hoffmann, T. Pohl, R. Koster, R. Blindt, P. Boeckstegers, and T. Heitzer
Implantation of paclitaxel-eluting stents in saphenous vein grafts: clinical and angiographic follow-up results from a multicentre study
Heart, March 1, 2007; 93(3): 331 - 334.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
P. Vermeersch, P. Agostoni, S. Verheye, P. Van den Heuvel, C. Convens, N. Bruining, F. Van den Branden, and G. Van Langenhove
Randomized Double-Blind Comparison of Sirolimus-Eluting Stent Versus Bare-Metal Stent Implantation in Diseased Saphenous Vein Grafts: Six-Month Angiographic, Intravascular Ultrasound, and Clinical Follow-Up of the RRISC Trial
J. Am. Coll. Cardiol., December 19, 2006; 48(12): 2423 - 2431.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
S. R. Dixon, C. L. Grines, and W. W. O'Neill
The Year in Interventional Cardiology
J. Am. Coll. Cardiol., April 18, 2006; 47(8): 1689 - 1706.
[Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
A. N. DeMaria, O. Ben-Yehuda, D. Berman, G. K. Feld, G. S. Ginsburg, B. H. Greenberg, W. Y.W. Lew, D. Sahn, and S. Tsimikas
Highlights of the Year in JACC 2005
J. Am. Coll. Cardiol., January 3, 2006; 47(1): 184 - 202.
[Full Text] [PDF]

Home page
 JAMAHome page
A. Colombo and J. Cosgrave
Paclitaxel-Eluting Stents in Complex Lesions
JAMA, September 14, 2005; 294(10): 1268 - 1270.
[Full Text] [PDF]

Home page
 Journal Watch CardiologyHome page
Drug-Eluting Stents in SVG Interventions
Journal Watch Cardiology, May 13, 2005; 2005(513): 3 - 3.
[Full Text]


HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 2005 by the American College of Cardiology Foundation.